A diamminedichloroplatinum compound in which the two ammine ligands and two chloro ligands are oriented in a cis planar configuration around the central platinum ion. An anticancer drug that interacts with, and forms cross-links between, DNA and proteins, it is used as a neoplasm inhibitor to treat solid tumours, primarily of the testis and ovary. Commonly but incorrectly described as an alkylating agent due to its mechanism of action (but it lacks alkyl groups).
Chemical ID:
MESH:D002945
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
[2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [FAM168A results in decreased susceptibility to Cisplatin]] which results in increased cleavage of PARP1 protein; [3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [FAM168A results in decreased susceptibility to Cisplatin]] which results in increased cleavage of PARP1 protein; [3-aminobenzamide results in decreased activity of PARP1 protein] which results in increased susceptibility to Cisplatin; [ACE2 protein inhibits the reaction [Cisplatin results in increased activity of CASP3 protein]] which results in decreased cleavage of PARP1 protein; [Berberine co-treated with Cisplatin] results in increased cleavage of PARP1 protein; [BIN1 protein results in decreased activity of PARP1 protein] which results in increased susceptibility to Cisplatin; [Cisplatin co-treated with CEP 8983] results in decreased activity of PARP1 protein; [Cisplatin co-treated with chrysin] results in increased cleavage of PARP1 protein; [Cisplatin co-treated with N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride] results in decreased activity of PARP1 protein; [Cisplatin results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein; [CITED2 results in decreased susceptibility to Cisplatin] which results in decreased cleavage of PARP1 protein; [Estradiol results in increased expression of PARP1 mRNA] which results in increased susceptibility to Cisplatin; [Proadifen co-treated with Cisplatin] results in increased cleavage of PARP1 protein; [S100A11 mutant form results in increased susceptibility to Cisplatin] which results in increased cleavage of PARP1 protein; [SLC39A8 protein affects the susceptibility to Cisplatin] which affects the cleavage of PARP1 protein; [SND1 mutant form results in increased susceptibility to Cisplatin] which results in increased cleavage of PARP1 protein; [trigonelline co-treated with Cisplatin] results in increased cleavage of PARP1 protein; [XAF1 protein results in increased susceptibility to Cisplatin] which results in increased cleavage of PARP1 protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased cleavage of PARP1 protein]; Acetylcysteine inhibits the reaction [[S100A11 mutant form results in increased susceptibility to Cisplatin] which results in increased cleavage of PARP1 protein]; Acetylcysteine inhibits the reaction [Arsenic Trioxide promotes the reaction [Cisplatin results in increased cleavage of PARP1 protein]]; Acetylcysteine inhibits the reaction [Cisplatin promotes the reaction [Arsenic Trioxide results in increased cleavage of PARP1 protein]]; Acetylcysteine inhibits the reaction [Cisplatin results in increased cleavage of PARP1 protein]; AKT1 protein inhibits the reaction [Cisplatin results in increased cleavage of PARP1 protein]; Arsenic Trioxide promotes the reaction [Cisplatin results in increased cleavage of PARP1 protein]; astilbin inhibits the reaction [Cisplatin results in increased cleavage of PARP1 protein]; BCL2 inhibits the reaction [Cisplatin results in increased cleavage of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Cisplatin co-treated with chrysin] results in increased cleavage of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [[S100A11 mutant form results in increased susceptibility to Cisplatin] which results in increased cleavage of PARP1 protein]; CAV1 protein promotes the reaction [Cisplatin results in increased cleavage of PARP1 protein]; CD40LG protein inhibits the reaction [Cisplatin promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]]; Cisplatin inhibits the reaction [Zinc binds to PARP1 protein]; Cisplatin promotes the reaction [Arsenic Trioxide results in increased cleavage of PARP1 protein]; Cisplatin promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]; Cisplatin promotes the reaction [Platinum binds to PARP1 protein]; CITED2 mutant form promotes the reaction [Cisplatin results in increased cleavage of PARP1 protein]; DICER1 mutant form inhibits the reaction [Cisplatin results in increased cleavage of PARP1 protein]; HSPA5 protein affects the reaction [Cisplatin results in increased cleavage of PARP1 protein]; IER5 protein promotes the reaction [Cisplatin results in increased cleavage of PARP1 protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Cisplatin results in increased activity of PARP1 protein]; Oleanolic Acid inhibits the reaction [Cisplatin results in increased cleavage of PARP1 protein]; S100A11 mutant form promotes the reaction [Cisplatin results in increased cleavage of PARP1 protein]; SND1 mutant form promotes the reaction [Cisplatin results in increased cleavage of PARP1 protein]; USP39 protein inhibits the reaction [Cisplatin results in increased expression of PARP1 protein modified form]
[Nicotinamide Mononucleotide co-treated with Cisplatin] results in decreased expression of PARP1 protein; arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased cleavage of PARP1 protein]; ART1 protein inhibits the reaction [Cisplatin results in increased cleavage of PARP1 protein]; aucubin inhibits the reaction [Cisplatin results in increased cleavage of PARP1 protein]; CARM1 protein affects the reaction [Cisplatin results in increased cleavage of PARP1 protein]; cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester inhibits the reaction [Cisplatin results in increased cleavage of PARP1 protein]; erdosteine inhibits the reaction [Cisplatin results in increased cleavage of PARP1 protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Cisplatin results in increased activity of PARP1 protein]; NQO1 gene mutant form inhibits the reaction [Cisplatin results in increased expression of PARP1 protein]; Oleanolic Acid inhibits the reaction [Cisplatin results in increased cleavage of PARP1 protein]; PRMT3 protein affects the reaction [Cisplatin results in increased cleavage of PARP1 protein]; SB 216763 inhibits the reaction [Cisplatin results in increased cleavage of PARP1 protein]
5-aminoisoquinoline inhibits the reaction [Cisplatin results in increased expression of PARP1 protein]; [CTNNA1 protein affects the susceptibility to Cisplatin] which results in increased cleavage of PARP1 protein; CTNNA1 gene affects the reaction [Cisplatin results in increased cleavage of PARP1 protein]; FSCN2 protein inhibits the reaction [[CTNNA1 protein affects the susceptibility to Cisplatin] which results in increased cleavage of PARP1 protein]; HNF1B protein inhibits the reaction [Cisplatin results in increased cleavage of PARP1 protein]
